UNSPSC 51263101: Atenolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50VV3VW0TI, chemically known as ici 66,082 but generally known as atenolol, which bears US NIH Compound Identifier 2249. Atenolol comes in many forms, including base, acetate, acid, diacetate, hydrochloride, methylboronate, and n-butylboronate. European Medicines Agency schedules Atenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05590MIG.

UNSPSC 51263101 Atenolol is a Commodity code that nominally names a single beta-blocker pharmaceutical product, but recent state and local procurement activity under this code shows a substantial mismatch: the two most recent opportunities posted involve naloxone procurement and pharmacy benefit program restructuring, neither of which relates to atenolol supply. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Both solicitations fall outside the scope of atenolol or single-entity pharmaceutical commodities; the code shows little relevant recent activity aligned with its nominal product scope.

Issuing bodies using this code include county health departments and state health and human services agencies. Geographic activity appears concentrated in Florida and Texas based on these two recent postings, though the sample size is too small to characterize a meaningful geographic pattern. The mismatch between the code designation (atenolol) and actual procurement focus (naloxone systems and pharmacy program restructuring) suggests either miscoding at the source or that this code is used inconsistently within state and local procurement systems. Vendors evaluating opportunities under UNSPSC 51263101 should verify code alignment with actual scope at the RFP or RFQ stage rather than relying on the code name alone.